Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Nitsch

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Nature|September 14, 2018
In vivo CRISPR editing with no detectable genome-wide off-target mutationsPinar Akcakaya, Maggie L Bobbin, Jimmy A Guo, et al.
Nature Communications|September 30, 2020
Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discoveryAnders Lundin, Michelle J Porritt, Himjyot Jaiswal, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 12, 2014
HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 responseBarak Rotblat, Amber L Southwell, Dagmar E Ehrnhoefer, et al.
Cell Reports|May 11, 2016
The Tumor Suppressor Hace1 Is a Critical Regulator of TNFR1-Mediated Cell FateLuigi Tortola, Roberto Nitsch, Mathieu J M Bertrand, et al.
Genes & Development|November 10, 2017
RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancerShuan Rao, Verena Sigl, Reiner Alois Wimmer, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Nature|September 14, 2018
In vivo CRISPR editing with no detectable genome-wide off-target mutationsPinar Akcakaya, Maggie L Bobbin, Jimmy A Guo, et al.
Nature Communications|September 30, 2020
Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discoveryAnders Lundin, Michelle J Porritt, Himjyot Jaiswal, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 12, 2014
HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 responseBarak Rotblat, Amber L Southwell, Dagmar E Ehrnhoefer, et al.
Cell Reports|May 11, 2016
The Tumor Suppressor Hace1 Is a Critical Regulator of TNFR1-Mediated Cell FateLuigi Tortola, Roberto Nitsch, Mathieu J M Bertrand, et al.
Genes & Development|November 10, 2017
RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancerShuan Rao, Verena Sigl, Reiner Alois Wimmer, et al.
Pageof 3